A recent study found that ALK inhibitors can increase the dosage of HLA associated proteins on the surface of ALK mutated lung cancer cells in both in vitro and in vivo experiments, while they can decrease PD-L1 levels on the surface of tumor cells by 75%. The gene discussed is CD274; the disease is lung carcinoma.